SBTX Stock Price, Silverback Therapeutics, . Quote, Chart

Market Summary

USD9.05+0.02

Delayed

0.22%

SBTX Stock Price

View Fullscreen

SBTX RSI Chart

SBTX Valuation

Market Cap

876.9M

Price/Earnings (Trailing)

-17.65

Price/Sales (Trailing)

29.2K

Price/Free Cashflow

-16.36

SBTX Price/Sales (Trailing)

SBTX Profitability

Return on Equity

-22.2%

Return on Assets

-21.84%

Free Cashflow Yield

-6.11%

SBTX Fundamentals

SBTX Revenue

Revenue (TTM)

30.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

SBTX Earnings

Earnings (TTM)

-49.7M

Earnings Growth (Yr)

31.21%

Earnings Growth (Qtr)

-43.58%

Breaking Down SBTX Revenue

Last 7 days

3.6%

Last 30 days

-0.2%

Last 90 days

26.4%

Trailing 12 Months

-38.1%

How does SBTX drawdown profile look like?

SBTX Financial Health

Current Ratio

60.9

SBTX Investor Care

Shares Dilution (1Y)

2.24%

Diluted EPS (TTM)

-0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	994.5K	673.0K	351.5K	30.0K
2022	4.5M	3.4M	2.4M	1.3M
2021	0	0	0	5.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Silverback Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 05, 2022	shawver laura	acquired	99,999	1.27	78,740	chief executive officer
May 02, 2022	odegard valerie	acquired	-	-	45,233	president and cso
May 02, 2022	hunder naomi	acquired	-	-	43,177	chief medical officer
May 02, 2022	shawver laura	acquired	-	-	68,107	chief executive officer
May 02, 2022	piazza jonathan	acquired	-	-	43,691	chief financial officer
May 02, 2022	hawkinson russ	acquired	-	-	28,335	sr. vice president of finance
Feb 01, 2022	piazza jonathan	acquired	-	-	11,250	chief financial officer
Feb 01, 2022	shawver laura	acquired	-	-	27,500	chief executive officer
Feb 01, 2022	hawkinson russ	acquired	-	-	7,500	sr. vice president of finance
Feb 01, 2022	hunder naomi	acquired	-	-	11,250	chief medical officer

Which funds bought or sold SBTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-3.39	148,525	333,765	-%
May 16, 2024	COMERICA BANK	new	-	1,431	1,431	-%
May 16, 2024	LEVIN CAPITAL STRATEGIES, L.P.	added	5.74	278,325	564,655	0.06%
May 16, 2024	AWM Investment Company, Inc.	new	-	1,022,000	1,022,000	0.13%
May 16, 2024	JANE STREET GROUP, LLC	added	4.72	460,448	943,592	-%
May 15, 2024	STATE STREET CORP	added	178	13,236,700	16,398,500	-%
May 15, 2024	Aquatic Capital Management LLC	new	-	11,242	11,242	-%
May 15, 2024	Woodline Partners LP	reduced	-39.25	481,724	4,106,270	0.04%
May 15, 2024	Paloma Partners Management Co	new	-	103,150	103,150	-%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	unchanged	-	61,336	132,247	-%

Are Funds Buying or Selling SBTX?

Are funds buying SBTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SBTX

No. of Funds

Unveiling Silverback Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 29, 2024	ra capital management, l.p.	11.3%	10,860,977	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Sep 25, 2023	ra capital management, l.p.	9.9%	9,459,678	SC 13D/A
Sep 01, 2023	bell robert g.	4.5%	4,313,965	SC 13D/A
Aug 31, 2023	ra capital management, l.p.	7.07%	6,759,678	SC 13D
Feb 14, 2023	nextech vi oncology scsp	2.0%	1,910,029	SC 13G/A
Feb 13, 2023	k2 principal fund, l.p.	2.20%	2,045,348	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Nov 30, 2022	orbimed advisors llc	8.3%	7,788,510	SC 13D/A
Nov 21, 2022	bell robert g.	9.1%	8,563,965	SC 13D

Recent SEC filings of Silverback Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 10, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	ARS	ARS

Silverback Therapeutics, Inc. News

Latest updates

Silverback Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-	-	-	-	10.00	5.00	-	189	464	663	-
Operating Expenses	29.0%	13,192	10,226	17,978	20,613	18,733	15,443	6,819	6,808	7,762	-41,117
S&GA Expenses	100.2%	93.00	-39,522	14,976	13,305	12,181	-7,120	2,926	2,458	2,339	-15,760
R&D Expenses	53.8%	5,234	3,404	3,002	7,308	6,552	4,710	3,893	4,350	5,423	-25,356
Interest Expenses	-	-	-	-	-	-	-	1,075	369	67.00	47.00
Net Income	-43.6%	-10,292	-7,168	-14,866	-17,370	-14,961	-14,429	-6,583	-6,420	-7,250	45,775
Net Income Margin	8.6%	-1.66	-1.81	-175.32*	-79.26*	-42.63*	-26.35*	10.80*	2.77*	-1.93*	-3.68*
Free Cashflow	60.8%	-6,793	-17,314	-12,806	-16,699	-12,622	-20,623	-5,712	-6,996	-6,946	28,661

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-2.4%	228	233	249	259	271	281	271	294	312	61.00	353	367	382	395
Current Assets	-2.4%	226	232	244	255	267	278	271	263	261	61.00	305	363	378	391
Cash Equivalents	-21.1%	56.00	71.00	61.00	119	88.00	211	37.00	45.00	52.00	60.00	301	360	375	25.00
Net PPE	7.3%	1.00	1.00	1.00	1.00	1.00	0.00	0.00	2.00	2.00	0.00	2.00	2.00	2.00	2.00
Liabilities	53.0%	4.00	2.00	11.00	10.00	10.00	9.00	4.00	15.00	19.00	17.00	20.00	17.00	14.00	12.00
Current Liabilities	55.4%	4.00	2.00	11.00	10.00	10.00	5.00	4.00	11.00	15.00	8.00	15.00	16.00	12.00	10.00
Shareholder's Equity	-3.0%	224	231	237	249	261	273	267	279	293	314	332	350	369	383
Retained Earnings	-7.8%	-141	-131	-124	-109	-91.90	-76.94	-248	-230	-210	-42.26	-162	-140	-115	-96.73
Additional Paid-In Capital	1.0%	366	362	362	358	353	349	517	511	505	11.00	495	490	484	480
Shares Outstanding	0.1%	97.00	96.00	96.00	95.00	94.00	94.00	31.00	30.00	30.00	30.00	35.00	35.00	35.00	35.00
Float	-	-	-	-	382	-	-	-	103	-	-	-	677	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	61.4%	-6,710	-17,405	-12,763	-16,669	-12,429	-20,497	-5,682	-6,974	-6,925	27,894	-19,119	-14,135	-12,201	-11,096	-7,029	-5,443	-7,628
Share Based Compensation	45.5%	3,315	2,278	2,609	2,098	2,250	4,763	460	356	264	-11,205	5,019	4,730	4,285	2,274	191	128	47.00
Cashflow From Investing	-132.7%	-8,513	26,039	-46,643	44,970	-111,546	-126	-30.00	-22.00	-21.00	40,738	-40,058	-700	-35.00	-247	-632	-5.00	-33.00
Cashflow From Financing	-85.7%	258	1,805	921	2,854	1,319	193,819	-1,556	-623	-908	52,819	148	319	-128	255,395	119,863	11,933	21,315

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SBTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue under collaboration agreements	$ 0	$ 20
Operating expenses:
Research and development (including related party amounts of $726 and $591, respectively)	5,234	6,552
General and administrative (including related party amounts of $93 and $337, respectively)	7,958	12,181
Total operating expenses	13,192	18,733
Loss from operations	(13,192)	(18,713)
Other income, net	2,900	3,752
Net loss	(10,292)	(14,961)
Change in unrealized gains and losses on available-for-sale securities	(173)	(339)
Comprehensive loss	$ (10,465)	$ (15,300)
Earnings Per Share, Basic	$ (0.11)	$ (0.16)
Earnings Per Share, Diluted	$ (0.11)	$ (0.16)
Weighted Average Number of Shares Outstanding, Basic	96,486,480	94,227,313
Weighted Average Number of Shares Outstanding, Diluted	96,486,480	94,227,313

SBTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 56,006	$ 70,971
Short term investments	167,626	157,389
Prepaid expenses and other current assets	2,609	3,366
Total current assets	226,241	231,726
Right-of-use asset	198	250
Fixed assets, net	616	574
Other assets	528	638
Total assets	227,583	233,188
Current liabilities:
Accounts payable and accrued liabilities (including related party amounts of $280 and $178, respectively)	3,498	2,154
Lease liability, current	217	237
Total current liabilities	3,715	2,391
Lease liability, net of current portion	0	37
Total liabilities	3,715	2,428
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value per share; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 96,574,049 and 96,414,963 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10	10
Additional paid-in capital	365,577	362,004
Accumulated other comprehensive (loss) gain, net	(124)	49
Accumulated deficit	(141,595)	(131,303)
Total stockholders' equity	223,868	230,760
Total liabilities and stockholders' equity	$ 227,583	$ 233,188

About Silverback Therapeutics, Inc.

0

WEBSITE	silverbacktx.com

Silverback Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Silverback Therapeutics, Inc.? What does SBTX stand for in stocks?

SBTX is the stock ticker symbol of Silverback Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silverback Therapeutics, Inc. (SBTX)?

As of Fri May 17 2024, market cap of Silverback Therapeutics, Inc. is 876.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SBTX stock?

You can check SBTX's fair value in chart for subscribers.

What is the fair value of SBTX stock?

You can check SBTX's fair value in chart for subscribers. The fair value of Silverback Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Silverback Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SBTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Silverback Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether SBTX is over valued or under valued. Whether Silverback Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Silverback Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SBTX.

What is Silverback Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SBTX's PE ratio (Price to Earnings) is -17.65 and Price to Sales (PS) ratio is 29.23 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SBTX PE ratio will change depending on the future growth rate expectations of investors.